• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current drug research reviews. >Molnupiravir in COVID-19: A Scoping Review
【24h】

Molnupiravir in COVID-19: A Scoping Review

机译：COVID-19 中的莫努匹韦：范围界定回顾

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: COVID-19, first detected in Wuhan, China, has evolved into a lifethreatening pandemic spread across six continents, with the global case count being more than 243 million, and mortality over 4.95 million, along with causing significant morbidity. It has initiated an era of research on repurposed drugs such as hydroxychloroquine, lopinavir/ritonavir, corticosteroids, remedesivir, ivermectin, alongside selective antivirals to treat or prevent COVID- 19. Molnupiravir is an orally available emerging antiviral drug considered highly promising for COVID-19. Methods and Results: We have performed a scoping review for the use of molnupiravir against SARS-CoV-2 and COVID-19. It acts by inhibiting RNA-dependent RNA polymerase (RdRp), and exhibits broad-spectrum antiviral activity. Preclinical studies have evaluated the therapeutic efficacy as well as prophylactic activity of molnupiravir against SARS CoV-2 in various animal models that include ferrets, hamsters, mice, immunodeficient mice implanted with human lung tissue and cell cultures, in various doses ranging from 5-300 mg/kg, and results have been encouraging. Initial evidence of safety and efficacy from early phase clinical studies has been encouraging too, and recent results from a large phase 3 global trial have shown significant benefits among symptomatic outpatients. Other late-phase clinical trials are still underway with the aim of establishing molnulpiravir as a therapeutic option for COVID-19, particularly for non-hospitalized patients. Conclusion and Relevance: On the basis of the limited evidence available as of now, molnupiravir could prove to be a promising oral therapy, worthy of further exploration of its utility for both treatment and prevention of COVID-19 in humans. Elaborate clinical evaluation is further warranted to confirm whether the results are replicable to the clinical scenario among outpatients to reduce the chance of progression to more severe disease.
机译：背景:COVID-19,首先检测到武汉,中国,已经演变成一种致命性的大流行遍布六大洲,全球病例数超过2.43亿,和死亡率超过495万这造成了严重的发病率。一个时代的研究类药物等糖皮质激素、remedesivir伊维菌素,与选择性治疗或抗病毒药物防止COVID - 19所示。新兴抗病毒药物被认为是可用的COVID-19高度承诺。结果:我们有执行范围审查molnupiravir反对SARS-CoV-2和的使用新型冠状病毒肺炎聚合酶(RdRp),表现出广谱抗病毒活性。评估治疗效果以及molnupiravir对预防活动在各种动物模型,包括SARS CoV-2雪貂、仓鼠、小鼠、免疫缺陷小鼠植入人体肺组织和细胞文化,在不同的剂量范围从5 - 300毫克/公斤,结果令人鼓舞。从早期阶段安全性和有效性的证据临床研究也一直鼓励,和最近的大型全球第三阶段试验的结果有症状之间表现出显著的好处吗门诊病人。仍在进行,目的是建立molnulpiravir作为一种治疗选择COVID-19,尤其是non-hospitalized病人。有限的证据的基础上的现在,molnupiravir可以被证明是一种很有前途的口服治疗,值得进一步探索治疗和预防其效用COVID-19在人类身上。进一步的确认吗临床场景得到相同的结果在门诊病人减少的可能性发展成更严重的疾病。

著录项

  • 来源
    《Current drug research reviews.》 |2022年第3期|203-214|共12页
  • 作者

    Shilpa Kaore; Shubham Atal;

  • 作者单位

    All India Institute of Medical Sciences,,Department of Pharmacology,,Bhopal,India,;

    All India Institute of Medical Sciences,Department of Pharmacology,Bhopal,India,;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 英语
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号